Scientific Publications

PancreasFest 2018

A Phase 1 Safety Study of SBP-101, a Polyamine Metabolic Inhibitor, for Pancreatic Ductal Adenocarcinoma

Niall C. Tebbutt, Dusan Kotasek, Mitesh J. Borad, Erkut Hasan Borazanci, Sheri Lynn Smith, Ajit K. Shah, Michael J. Walker, Michael T. Cullen, Suzanne Gagnon

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).

View/download abstract »

https://meetinglibrary.asco.org/record/164948/abstract

Digestive Disease Week 2017

SBP-101 Produces Exocrine Pancreatic Atrophy and Insufficiency While Preserving Islet Cell Function in Dogs

Michael J Walker MD, Suzanne Gagnon MD, Anthony Kiorpes DVM, PhD, Michael Cullen MD, Janet Wiegand BS, Raymond Bergeron PhD

SBP-101 Induces Apoptosis in Mouse Pancreatic Acinar Cells and Inhibits Polyamine-induced Proliferation

A. Sareen, A. Saluja, A. Shah, R. Dawra

American Pancreatic Association 2015

Evaluation of Human Pancreatic Cancer Cell Viability Following Administration of SBP-101 in the Presence and Absence of Gemcitabine and Nab-Paclitaxel

C. Baker, S. Arora, S. Gagnon, M. Cullen, A. Shah

PancreasFest 2015

Efficacy of SBP-101 Against Human Pancreatic Ductal Adenocarcinoma Following Orthotopic Implantation of L3.6pl Pancreatic Cancer Cells into Nude Mice

Ajit K. Shah, Michael T. Cullen, Cheryl H. Baker

AACR 2014 abstract #3128

Efficacy of Diethyldihydroxyhomospermine Against Human Pancreatic Adenocarcinoma Using Orthotopic Implantation of Human Pancreatic L3.6pl Cells into the Pancreas of Nude Mice

Shah AK, Cullen MT, Baker CH.

Poster Abstract